KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Finished Goods (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Finished Goods for 9 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • Quarterly Finished Goods fell 78.53% to $2.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Sep 2025, down 78.53% year-over-year, with the annual reading at $4.2 million for FY2024, 58.89% down from the prior year.
  • Finished Goods hit $2.0 million in Q3 2025 for Bionano Genomics, down from $3.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $19.8 million in Q2 2022 to a low of $300000.0 in Q1 2021.
  • Historically, Finished Goods has averaged $9.6 million across 5 years, with a median of $9.1 million in 2024.
  • Biggest five-year swings in Finished Goods: crashed 79.63% in 2021 and later skyrocketed 4943.0% in 2022.
  • Year by year, Finished Goods stood at $6.1 million in 2021, then soared by 186.06% to $17.4 million in 2022, then crashed by 41.08% to $10.2 million in 2023, then tumbled by 58.89% to $4.2 million in 2024, then tumbled by 53.63% to $2.0 million in 2025.
  • Business Quant data shows Finished Goods for BNGO at $2.0 million in Q3 2025, $3.3 million in Q2 2025, and $3.3 million in Q1 2025.